Searchable abstracts of presentations at key conferences in endocrinology

ea0081p214 | Thyroid | ECE2022

Severe refractory active thyroid eye disease: an unmet clinical need in Europe

Tzoulis Ploutarchos , Dosiou Chrysoula

Introduction: Moderate to severe thyroid eye disease (TED) has a significant impact on quality of life. In some cases, TED is resistant to systemic glucocorticoids, the mainstay of treatment since the 1950s, requiring alternative therapies. We describe here a patient with active severe TED who is refractory to various treatments.Case presentation: A 48-year-old non-smoker male, with a long history of psoriasis, vitiligo and atrophic gastritis, presented ...

ea0092op-04-02 | Oral Session 4: Young Investigators / Clinical and Translational | ETA2023

Teprotumumab-Related adverse events in thyroid eye disease: a multi-center real world study

Shah Shreya , Amarikwa Linus , Sears Connie , Ugradar Shoaib , Clauss Kevin , Rajjoub Raneem , Kang Julia , Tamhankar Madhura , Briceno Cesar , Harrison Andrew , Dosiou Chrysoula , Cockerham Kimberly , Wester Sara , Douglas Raymond , Kossler Andrea

Objectives: The insulin-like growth factor I receptor (IGF-1R) plays a significant role in the pathology of thyroid eye disease (TED), an autoimmune disorder characterized by orbital inflammation. Teprotumumab, a human monoclonal antibody targeting IGF-1R, has demonstrated efficacy in treating moderate-to-severe TED. A significant proportion of patients experienced adverse events (AEs), with 74% and 85% reporting an AE and 12% and 5% reporting serious AEs in Phase 2 and 3 tria...